Evaluation of the ability of two transfection reagents to deliver small interfering RNA molecules to equine and guinea pig cartilage in vitro.

This study evaluates the efficiency of two commercially available transfection reagents in delivering small interfering RNA (siRNA) molecules to chondrocytes in both monolayer cultures and full-thickness cartilage biopsies obtained from guinea pigs and horses.

Study Approach

• The experiment included cartilage specimens from both one-month-old and adult guinea pigs, as well as from healthy adult horses.
• Monolayer chondrocytes and full-thickness cartilage biopsies were treated with one of two siRNA transfection complexes following the manufacturers’ guidelines.
• The research team also exposed chondrocytes to twice the recommended amount of a proprietary siRNA molecule.
• Full-thickness cartilage biopsies were then treated with different concentrations of the proprietary siRNA and the cationic liposome siRNA.
• Fluorescent siRNA duplexes were used to quantify transfected cells using flow cytometry, and to observe the distribution and depth of in situ transfection via fluorescent microscopy.

Results of the Study

• More than 90% of monolayer chondrocytes were transfected with both transfection reagents.
• In chondrocyte biopsies, over 50% transfection efficiency was achieved only by using the proprietary molecule. Meanwhile, using the cationic liposome yielded less than 20% efficiency.
• Cells treated with the proprietary molecule were consistently fluorescent across all zones, indicating successful transfection throughout. On the other hand, chondrocytes transfected with the cationic liposome were restricted to the exterior surfaces of the biopsies.

Conclusion of the Study

• Both transfection reagents were capable of robust transfection in chondrocytes in a monolayer. However, for full-thickness transfection of biopsies, only the proprietary molecule demonstrated effective results.
• This suggests that the proprietary molecule could potentially provide meaningful transcript reduction via RNAi, creating a promising avenue for future research in the field of molecular biology and genetic science.